A systematic review and meta-analysis of fetal outcomes following the administration of influenza A/H1N1 vaccination during pregnancy

2017 ◽  
Vol 141 (2) ◽  
pp. 141-150 ◽  
Author(s):  
Chuan Zhang ◽  
Xiaodong Wang ◽  
Dan Liu ◽  
Lingli Zhang ◽  
Xin Sun
Keyword(s):  
Systematic Review ◽  
Influenza A ◽  
Meta Analysis ◽  
Fetal Outcomes ◽  
Influenza A H1n1

scholarly journals Prevalence of diabetes in the 2009 influenza A (H1N1) and the Middle East respiratory syndrome coronavirus: a systematic review and meta-analysis

2016 ◽  
Vol 5 (3) ◽  
Author(s):  
Alaa Badawi ◽  
Sueng Gwan Ryoo
Keyword(s):  
Systematic Review ◽  
Middle East ◽  
Influenza A ◽  
Meta Analysis ◽  
Middle East Respiratory Syndrome ◽  
Global Public Health ◽  
Epidemiologic Evidence ◽  
Severe Acute Respiratory Infection ◽  
Influenza A H1n1 ◽  
Prevalence Of Obesity

Over the past two decades a number of severe acute respiratory infection outbreaks such as the 2009 influenza A (H1N1) and the Middle East respiratory syndrome coronavirus (MERS-CoV) have emerged and presented a considerable global public health threat. Epidemiologic evidence suggests that diabetic subjects are more susceptible to these conditions. However, the prevalence of diabetes in H1N1 and MERS-CoV has not been systematically described. The aim of this study is to conduct a systematic review and meta-analysis of published reports documenting the prevalence of diabetes in H1N1 and MERS-CoV and compare its frequency in the two viral conditions. Meta-analysis for the proportions of subjects with diabetes was carried out in 29 studies for H1N1 (n=92,948) and 9 for MERS-CoV (n=308). Average age of H1N1 patients (36.2±6.0 years) was significantly younger than that of subjects with MERS-CoV (54.3±7.4 years, P<0.05). Compared to MERS-CoV patients, subjects with H1N1 exhibited 3-fold lower frequency of cardiovascular diseases and 2- and 4-fold higher prevalence of obesity and immunosuppression, respectively. The overall prevalence of diabetes in H1N1 was 14.6% (95% CI: 12.3- 17.0%; P<0.001), a 3.6-fold lower than in MERS-CoV (54.4%; 95% CI: 29.4-79.5; P<0.001). The prevalence of diabetes among H1N1 cases from Asia and North America was ~two-fold higher than those from South America and Europe. The prevalence of diabetes in MERS-CoV cases is higher than in H1N1. Regional comparisons suggest that an etiologic role of diabetes in MERS-CoV may exist distinctive from that in H1N1.

scholarly journals Hospitalization Fatality Risk of Influenza A(H1N1)pdm09: A Systematic Review and Meta-Analysis

2015 ◽  
Vol 182 (4) ◽  
pp. 294-301 ◽  
Author(s):  
Jessica Y. Wong ◽  
Heath Kelly ◽  
Chung-Mei M. Cheung ◽  
Eunice Y. Shiu ◽  
Peng Wu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Influenza A ◽  
Meta Analysis ◽  
Fatality Risk ◽  
Influenza A H1n1

scholarly journals Venous Thromboembolism in COVID-19 Compared to Non-COVID-19 Cohorts: A Systematic Review with Meta-Analysis

2021 ◽  
Vol 10 (21) ◽  
pp. 4925
Author(s):  
Antonella Tufano ◽  
Domenico Rendina ◽  
Veronica Abate ◽  
Aniello Casoria ◽  
Annachiara Marra ◽  
...  
Keyword(s):  
Systematic Review ◽  
Venous Thromboembolism ◽  
Influenza A ◽  
Respiratory Tract Infections ◽  
Retrospective Studies ◽  
Meta Analysis ◽  
Risk Difference ◽  
Influenza A H1n1 ◽  
High Incidence ◽  
Tract Infections

Background: A high incidence of venous thromboembolism (VTE) is reported in hospitalized COVID-19 patients, in particular in patients admitted to the intensive care unit (ICU). In patients with respiratory tract infections, including influenza A (H1N1), many studies have demonstrated an increased incidence of thromboses, but evidence is lacking regarding the risk difference (RD) of the occurrence of VTE between COVID-19 and non-COVID-19 patients. Methods: In this systematic review with meta-analysis, we evaluated the RD of the occurrence of VTE, pulmonary embolism (PE), and deep venous thrombosis (DVT) between COVID-19 and other pulmonary infection cohorts, in particular H1N1, and in an ICU setting. We searched for all studies comparing COVID-19 vs. non-COVID-19 regarding VTE, PE, and DVT. Results: The systematic review included 12 studies and 1,013,495 patients. The RD for VTE in COVID-19 compared to non-COVID-19 patients was 0.06 (95% CI 0.11–0.25, p = 0.011, I2 = 97%), and 0.16 in ICU (95% CI 0.045–0.27, p = 0.006, I2 = 80%). The RD for PE between COVID-19 and non-COVID-19 patients was 0.03 (95% CI, 0.006–0.045, p = 0.01, I2 = 89%). The RD for PE between COVID-19 and non-COVID-19 patients was 0.021 in retrospective studies (95% CI 0.00–0.04, p = 0.048, I2 = 92%) and 0.11 in ICU studies (95% CI 0.06–0.16, p < 0.001, I2 = 0%). Conclusions: The growing awareness and understanding of a massive inflammatory response combined with a hypercoagulable state that predisposes patients to thrombosis in COVID-19, in particular in the ICU, may contribute to a more appropriate strategy of prevention and earlier detection of the thrombotic events.

scholarly journals Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: A systematic review and meta-analysis

Vaccine ◽  
2017 ◽  
Vol 35 (16) ◽  
pp. 1996-2006 ◽  
Author(s):  
Louise E. Lansbury ◽  
Sherie Smith ◽  
Walter Beyer ◽  
Emina Karamehic ◽  
Eva Pasic-Juhas ◽  
...  
Keyword(s):  
Systematic Review ◽  
Pandemic Influenza ◽  
Influenza A ◽  
Meta Analysis ◽  
Influenza A H1n1

scholarly journals Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis

2011 ◽  
Vol 5 (5) ◽  
pp. 299-305 ◽  
Author(s):  
J. Kevin Yin ◽  
Gulam Khandaker ◽  
Harunor Rashid ◽  
Leon Heron ◽  
Iman Ridda ◽  
...  
Keyword(s):  
Systematic Review ◽  
Pandemic Influenza ◽  
Influenza A ◽  
Meta Analysis ◽  
Influenza A H1n1
Sign in / Sign up

Export Citation Format

Share Document